Upload Once. Track Forever. Never Miss a Signal.
CrisPRO Oncology: From VUS to Validated Care Plan
Replace static genomic reports with continuous agentic intelligence. From initial analysis to Month 18+, our agents never stop working—tracking CA-125 kinetics, monitoring ctDNA mutations, matching new trials, and alerting you to resistance 3-6 weeks before imaging confirms it.
The Problem: Genomic Testing is Stuck in 2015
Static reports are point-in-time snapshots that capture mutations once, generate recommendations once, then sit untouched.
One-Time Analysis
Report generated once, then forgotten. No updates, no continuous monitoring.
Resistance Detected Late
3-6 months after it starts. Window to intervene is gone.
Trials Missed
Can't manually track 20,000+ active studies. Perfect matches slip through.
The Solution: Continuous Agentic Intelligence
What if your genomic report was alive? Upload once, and our 8-agent pipeline orchestrates everything—from Day 1 to Month 18+. The agents never stop working.
Day 1: Instant Analysis
Upload report → 30 seconds → Complete care plan with biomarkers, drug rankings, trials, nutrition.
Month 18+: Never Stops
Continuous monitoring: CA-125 kinetics, ctDNA mutations, trial matching, resistance alerts 3-6 weeks early.
Live Monitoring: Patient X s Journey
See how continuous intelligence tracks CA-125 kinetics, detects resistance mutations, matches new trials, and alerts oncologists to critical changes—automatically.
Continuous Monitoring Dashboard
Upload Once. Track Forever. Never Miss a Signal. • Patient AK
3 consecutive measurements ±10% - Expected decline, observed plateau
Last update: 1/13/2026
Resistance mutation: KRAS G12D (MAPK pathway) - RR=1.97 for platinum resistance
Last update: 1/19/2026
CT scan shows stable disease - agents detected resistance 6 weeks before imaging
Last update: 12/30/2025
NCT05678901: PARP + ATR combo (94% mechanism fit) - Added automatically when trial opened
Last update: 1/18/2026
Active Alerts & Insights
3 ActiveCA-125 Plateau Detected
HIGHExpected: Continue decline to <500. Observed: Flat trajectory at 900 for 3 cycles. Action: Consider early resistance intervention.
Recommended Action:
Increase ctDNA monitoring frequency, consider PARP switch NOW
Resistance Mutation: KRAS G12D
HIGHNew ctDNA mutation detected at 0.8% VAF. Associated with platinum resistance (RR=1.97, p<0.05). Re-ranking drugs, prioritizing MEK/RAF inhibitors.
Recommended Action:
High priority - resistance mechanism identified, update care plan
New Trial Match: NCT05678901
MEDIUMPARP + ATR inhibitor combo specifically for DNA repair-deficient ovarian cancer. Mechanism fit: 94% (DDR pathway vector alignment). Status: RECRUITING.
Recommended Action:
Added to dashboard, oncologist notified
Monitoring Timeline
The 8-Agent Pipeline: From Upload to Care Plan
Experience how our agent swarm orchestrates data extraction, biomarker calculation, resistance prediction, synthetic lethality detection, drug ranking, trial matching, nutrition planning, and continuous monitoring—all in one seamless cascade.
Intelligence Cascade
Autonomous oncology orchestration for AK • 0.0s elapsed
SAE Intelligence Analysis
Sparse Autoencoder feature attribution for biological interpretation
🎯 Experience Our Capabilities
Try it live: See how our AI-powered oncology platform matches patients to the right therapies using mechanism-based intelligence. Every recommendation shows WHY (eligibility + fit + conditions), not just WHAT.
Match Patients to Therapies
Mechanism-Based Drug Ranking
Experience how Match Patients to Therapies works with real-time AI-powered analysis
Explore Other Products
See How Healthcare Uses CrisPRO
Discover how different industries leverage CrisPRO to transform their workflows